182 related articles for article (PubMed ID: 23624801)
1. Antibody-dependent cell lysis by NK cells is preserved after sarcoma-induced inhibition of NK cell cytotoxicity.
Pahl JH; Ruslan SE; Kwappenberg KM; van Ostaijen-Ten Dam MM; van Tol MJ; Lankester AC; Schilham MW
Cancer Immunol Immunother; 2013 Jul; 62(7):1235-47. PubMed ID: 23624801
[TBL] [Abstract][Full Text] [Related]
2. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.
Pahl JH; Ruslan SE; Buddingh EP; Santos SJ; Szuhai K; Serra M; Gelderblom H; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
Clin Cancer Res; 2012 Jan; 18(2):432-41. PubMed ID: 22090361
[TBL] [Abstract][Full Text] [Related]
3. Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells.
Boerman GH; van Ostaijen-ten Dam MM; Kraal KC; Santos SJ; Ball LM; Lankester AC; Schilham MW; Egeler RM; van Tol MJ
Cancer Immunol Immunother; 2015 May; 64(5):573-83. PubMed ID: 25854581
[TBL] [Abstract][Full Text] [Related]
4. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells.
Buddingh EP; Schilham MW; Ruslan SE; Berghuis D; Szuhai K; Suurmond J; Taminiau AH; Gelderblom H; Egeler RM; Serra M; Hogendoorn PC; Lankester AC
Cancer Immunol Immunother; 2011 Apr; 60(4):575-86. PubMed ID: 21240486
[TBL] [Abstract][Full Text] [Related]
6. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions.
Garcia-Iglesias T; Del Toro-Arreola A; Albarran-Somoza B; Del Toro-Arreola S; Sanchez-Hernandez PE; Ramirez-Dueñas MG; Balderas-Peña LM; Bravo-Cuellar A; Ortiz-Lazareno PC; Daneri-Navarro A
BMC Cancer; 2009 Jun; 9():186. PubMed ID: 19531227
[TBL] [Abstract][Full Text] [Related]
7. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB
Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094
[TBL] [Abstract][Full Text] [Related]
9. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
10. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S
BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052
[TBL] [Abstract][Full Text] [Related]
11. Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells.
Zhang H; Cui Y; Voong N; Sabatino M; Stroncek DF; Morisot S; Civin CI; Wayne AS; Levine BL; Mackall CL
J Immunother; 2011 Mar; 34(2):187-95. PubMed ID: 21304401
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells.
Castriconi R; Cantoni C; Della Chiesa M; Vitale M; Marcenaro E; Conte R; Biassoni R; Bottino C; Moretta L; Moretta A
Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4120-5. PubMed ID: 12646700
[TBL] [Abstract][Full Text] [Related]
13. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer.
Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
J Immunol; 2005 Oct; 175(8):5541-50. PubMed ID: 16210663
[TBL] [Abstract][Full Text] [Related]
15. Activation of natural killer cells by hepatitis C virus particles in vitro.
Farag MM; Weigand K; Encke J; Momburg F
Clin Exp Immunol; 2011 Sep; 165(3):352-62. PubMed ID: 21682720
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus-infected cells downregulate NKp30 and inhibit ex vivo NK cell functions.
Holder KA; Stapleton SN; Gallant ME; Russell RS; Grant MD
J Immunol; 2013 Sep; 191(6):3308-18. PubMed ID: 23960237
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation.
Zhang C; Zhang J; Niu J; Zhang J; Tian Z
Cytokine; 2008 Apr; 42(1):128-36. PubMed ID: 18280748
[TBL] [Abstract][Full Text] [Related]
18. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors.
Poggi A; Prevosto C; Massaro AM; Negrini S; Urbani S; Pierri I; Saccardi R; Gobbi M; Zocchi MR
J Immunol; 2005 Nov; 175(10):6352-60. PubMed ID: 16272287
[TBL] [Abstract][Full Text] [Related]
19. Nutlin-3a Enhances Natural Killer Cell-Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors.
Veneziani I; Infante P; Ferretti E; Melaiu O; Battistelli C; Lucarini V; Compagnone M; Nicoletti C; Castellano A; Petrini S; Ognibene M; Pezzolo A; Di Marcotullio L; Bei R; Moretta L; Pistoia V; Fruci D; Barnaba V; Locatelli F; Cifaldi L
Cancer Immunol Res; 2021 Feb; 9(2):170-183. PubMed ID: 33303573
[TBL] [Abstract][Full Text] [Related]
20. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
Omer N; Nicholls W; Ruegg B; Souza-Fonseca-Guimaraes F; Rossi GR
Front Immunol; 2021; 12():791206. PubMed ID: 34804076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
